The FDA approved Leqembi Iqlik (lecanemab-irmb) as an at-home subcutaneous starting dose for early Alzheimer's disease on July 13, 2026, letting patients begin treatment without an initial IV infusion visit, according to the FDA's approval notice. The change affects how treatment begins, not what the drug does — lecanemab still targets the same disease process, but the first weeks of dosing can now happen at home under a caregiver's or patient's own hand. For people with mild cognitive impairment or mild dementia due to Alzheimer's, this removes a logistical barrier that kept some patients from starting treatment at all. It does not remove the monitoring the drug has always required, and understanding that distinction matters before anyone picks up an autoinjector.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from FDA — Use this primary source to verify the official guidance.
- Explore the official data from FDA — Use this primary source to review the underlying data.
Table of Contents
- What the at-home starting dose actually involves
- Why monitoring doesn't disappear just because the needle moved home
- Who should be cautious, and why blood thinners matter
- How the autoinjector performs in practice
- When this becomes available and what it changes practically
- Frequently Asked Questions
What the at-home starting dose actually involves
The approved starting regimen is 500 mg once weekly, delivered as two separate 250 mg injections, each taking about 15 seconds to administer, according to Eisai and Biogen's announcement. The patient or a caregiver gives the injections using the Leqembi Iqlik autoinjector, the same device used for ongoing treatment. After this starting-dose period, patients move to maintenance dosing of 360 mg once weekly through the same autoinjector, and the FDA's prescribing label confirms that patients can switch between IV and subcutaneous administration throughout the course of therapy.
This gives families flexibility if a patient's situation changes — for example, moving from a clinic-based IV schedule to home injections, or back again. This starting-dose approval builds on an earlier one: subcutaneous maintenance dosing alone was approved around August 2025 and launched commercially on October 6, 2025, at a wholesale cost of $375 per autoinjector, or roughly $19,500 a year, per the Biogen announcement. The new piece is specifically the ability to start treatment this way, not just continue it.
Why monitoring doesn't disappear just because the needle moved home
Removing the IV visit does not remove the safety work behind it. The FDA's label calls for enhanced clinical vigilance for ARIA — amyloid-related imaging abnormalities, a type of brain swelling or bleeding that can show up on MRI scans — during the first 14 weeks of treatment, with MRI monitoring required to catch it early because ARIA can be serious or fatal. That 14-week window spans the entire starting-dose period and the early part of maintenance dosing, meaning the highest-risk stretch of treatment is also the stretch most likely to happen without a clinician present for the injection itself.
The MRI scans still have to happen on schedule at a clinic or imaging center; only the injection has moved home. Before starting, the FDA advises testing patients for the ApoE ε4 gene variant, because people with two copies of this allele have a higher rate of ARIA than those with one copy or none. This test is a one-time blood draw that helps a clinician and family understand the patient's individual risk level going into treatment, not an ongoing requirement.
Who should be cautious, and why blood thinners matter
One specific risk factor deserves its own attention: anticoagulant medications. The FDA's safety information notes that patients taking blood thinners alongside Leqembi had a higher rate of intracerebral hemorrhage — bleeding inside the brain — than patients on a placebo.
For a family managing medications at home, this is a conversation to have with the prescribing physician before the first injection, not after. A few practical checks matter before starting at-home dosing: None of this requires a hospital visit, but it does require coordination with the prescribing clinician before the starting dose begins at home.
- Confirm ApoE ε4 genotype testing has been completed and discussed with the prescriber.
- Review every current medication, especially blood thinners, with the care team.
- Confirm the MRI monitoring schedule for the first 14 weeks is booked, not just recommended.
- Identify who will give the injections — the patient or a caregiver — and confirm they've been shown the autoinjector technique.
How the autoinjector performs in practice
Eisai and Biogen cited an acceptability study showing that 94% of patients and care partners rated the autoinjector device easy to use, with high satisfaction and confidence in self- or caregiver-administration. That figure is the companies' basis for extending at-home use to the starting dose, not just maintenance treatment.
For a caregiver who has never given an injection, this suggests the device itself is not the primary hurdle — training and the monitoring schedule are the parts that need planning. A 15-second injection, twice weekly during the starting period, is a short physical task; coordinating MRI appointments and watching for ARIA symptoms is the longer-term responsibility.
When this becomes available and what it changes practically
Eisai and Biogen stated they planned to launch the at-home starting dose commercially in late August 2026, following the July 13, 2026 approval. For patients and families, the practical shift is straightforward: early Alzheimer's patients starting lecanemab no longer need an initial infusion-center visit to begin treatment, but they still need baseline ApoE4 testing and the full MRI-based ARIA monitoring schedule the label requires.
That combination — home-based injection paired with clinic-based imaging — is the actual shape of the new option. It shortens the list of required clinic visits without shortening the list of required safety checks.
Frequently Asked Questions
Does the at-home starting dose replace the need for MRI scans?
No. The FDA's label still requires MRI-based monitoring for ARIA during the first 14 weeks of treatment, regardless of where the injections happen.
Can a patient switch between IV and subcutaneous dosing later?
Yes. The FDA prescribing label allows patients to switch between IV and subcutaneous administration throughout treatment.
Who faces a higher risk of ARIA with this drug?
Patients who are homozygous for the ApoE ε4 allele have a higher incidence of ARIA, which is why the FDA advises genotype testing before starting.
When did the at-home starting dose become available?
The FDA approved it on July 13, 2026, with Eisai and Biogen planning commercial launch in late August 2026.
You Might Also Like
- Day-One Subcutaneous Leqembi for Early Alzheimer’s in 2026: Safety and Monitoring Questions for People With Mild Cognitive Impairment
- Maine’s 2026 ECHO Training for Dementia Risk Reduction: Local Action Questions for Family Caregivers
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Changed and What Comes Next for People With Mild Cognitive Impairment
